These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35675604)

  • 1. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.
    Stewart EA; Lukes AS; Venturella R; Arjona Ferreira JC; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Obstet Gynecol; 2022 Jun; 139(6):1070-1081. PubMed ID: 35675604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    Obstet Gynecol; 2022 Dec; 140(6):920-930. PubMed ID: 36357960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HOD; Li Y; McKain L; Arjona Ferreira JC; Langenberg AGM; Wagman RB; Stewart EA
    N Engl J Med; 2021 Feb; 384(7):630-642. PubMed ID: 33596357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study.
    Stewart EA; Al-Hendy A; Lukes AS; Madueke-Laveaux OS; Zhu E; Proehl S; Schulmann T; Marsh EE
    Am J Obstet Gynecol; 2024 Feb; 230(2):237.e1-237.e11. PubMed ID: 37863160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
    Al-Hendy A; Venturella R; Arjona Ferreira JC; Li Y; Soulban G; Wagman RB; Lukes AS
    Am J Obstet Gynecol; 2023 Dec; 229(6):662.e1-662.e25. PubMed ID: 37666383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
    Becker CM; Johnson NP; As-Sanie S; Arjona Ferreira JC; Abrao MS; Wilk K; Imm SJ; Mathur V; Perry JS; Wagman RB; Giudice LC
    Hum Reprod; 2024 Mar; 39(3):526-537. PubMed ID: 38243752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial.
    Osuga Y; Enya K; Kudou K; Tanimoto M; Hoshiai H
    Obstet Gynecol; 2019 Mar; 133(3):423-433. PubMed ID: 30741797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids.
    Al-Hendy A; Lukes AS; Venturella R; Villarroel C; McKain L; Li Y; Wagman RB; Stewart EA
    J Comp Eff Res; 2023 Aug; 12(8):e230069. PubMed ID: 37477173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies.
    Al-Hendy A; Lukes AS; Poindexter AN; Venturella R; Villarroel C; Critchley HO; Li Y; McKain L; Arjona Ferreira JC; Langenberg AG; Wagman RB; Stewart EA
    Pain Manag; 2023 Apr; 13(4):205-211. PubMed ID: 37183454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.
    Hoshiai H; Seki Y; Kusumoto T; Kudou K; Tanimoto M
    BMC Womens Health; 2021 Oct; 21(1):375. PubMed ID: 34711224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.
    Venturella R; Rechberger T; Zatik J; Wagman RB; Zhu E; Rakov VG; Petraglia F
    Gynecol Endocrinol; 2023 Aug; 39(1):2249107. PubMed ID: 37634528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids.
    Syed YY
    Drugs; 2022 Oct; 82(15):1549-1556. PubMed ID: 36331779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Giudice LC; As-Sanie S; Arjona Ferreira JC; Becker CM; Abrao MS; Lessey BA; Brown E; Dynowski K; Wilk K; Li Y; Mathur V; Warsi QA; Wagman RB; Johnson NP
    Lancet; 2022 Jun; 399(10343):2267-2279. PubMed ID: 35717987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y; Enya K; Kudou K; Hoshiai H
    Fertil Steril; 2019 Nov; 112(5):922-929.e2. PubMed ID: 31594635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long-term extension study: A descriptive subgroup analysis in women with anemia at baseline.
    Venturella R; Lukes AS; Wu R; McLean R; Rakov VG; Al-Hendy A
    Int J Gynaecol Obstet; 2024 May; 165(2):431-441. PubMed ID: 38576220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
    Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
    Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical trial of alternative relugolix administration for uterine leiomyoma prior to surgically treatment: a study protocol for Non-Adverse Relugolix Administration (NARA) trial.
    Kawahara N; Kawaguchi R; Yamamoto K; Nishikawa K; Matsuoka M; Maehana T; Fukui Y; Yamanaka S; Sugimoto S; Iwai K; Yamada Y; Kurakami H; Hirata T; Takashima R; Suzuki S; Asada K; Kasahara M; Kimura F
    Trials; 2024 Jan; 25(1):68. PubMed ID: 38243317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M; Chen HY; Chiang YF; Badary OA; Hsia SM; Al-Hendy A
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.